30 Years of Wilms Tumor Experience at One Center in Türkiye’s Central Anatolia Region

Year 2024, Volume: 23 Issue: 4, 344 - 348, 20.02.2024

Şefika Akyol , Gül Pelin Odabaş , Alper Özcan , Ebru Yılmaz , Zehra Filiz Karaman , Figen Öztürk , Hülya Akgün , Ahmet Burak Doğan Celalettin Eroğlu , Ekrem Ünal , Musa Karakükçü

https://doi.org/10.26650/jchild.2023.1308863

Abstract

Objective: The current study aims to evaluate the clinical presentation, treatment, and follow-up of children with Wilms Tumor (WT) who had been admitted to Erciyes University, Faculty of Medicine Department of Pediatric Hematology and Oncology hospital, a tertiary center in the central Anatolia region of Türkiye. The study assesses the survival data and features that have had an impact on survival.
Materials and Methods: The current study has been planned as a retrospective observational evaluation of patients admitted to the Pediatric Hematology and Oncology Center between 1991-2021.
Results: The study retrospectively evaluated a total of 48 patients in terms of demographic characteristics, presentation findings, tumor stages, histopathologies, and survival rates. Patients with an unfavorable histology had a 66.7% chance of both event-free survival (EFS) and overall survival (OS), which is lower than the respective 85.2% and 92.1% odds of EFS and OS for the favorable histology group. However, this is not statistically significant (p = 0.20 for EFS and p = 0.05 for OS). Regarding the impact of stage on survival rates, the EFS and OS for patients with the low-stage disease were 88% and 95.7%, respectively. These rates were significantly superior to those at an advanced stage of the disease, whose EFS and OS were 63.1% and 60.9%, respectively (p = 0.042 for EFS, p = 0.005 for OS).
Conclusion: Wilms tumor at an advanced stage and with an unfavorable histology are the major factors resulting in poor survival rates.

Keywords

Wilms Tumor, Event-Free Survival, Overall Survival, Unfavorable Histology

Supporting Institution

no

Project Number

no

Thanks

no

References

• Fernandez CV, Geller JI, Ehrlich PF, et al. Renal Tumors, in Pizzo&Poplack’s Pediatric Oncology.2021, Philadelphia.pp 525-540. google scholar
• Özyörük D, Emir S. The management of bilateral Wilms tumor. Transl Pediatr. 2014;3(1):34-38. google scholar
• Akyuz C, Yalcin B, Yildiz I, et al. Treatment of Wilms tumor: a report from the Turkish Pediatric Oncology Group (TPOG). Pediatr Hematol Oncol, 27(3): p. 161-178, 2010. google scholar
• Aydın B, Akyüz C, Yalçın B, Ekinci S, Oğuz B, Akçören Z, Yıldız F, Varan A, Kurucu N, Büyükpamukçu M, Kutluk T. Bilateral Wilms tumors: Treatment results from a single center. Turk J Pediatr. 2019;61(1):44-51. google scholar
• Dome JS, Graf N, Geller JI, et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol. 2015 Sep 20;33(27):2999-3007. google scholar
• Kara B, Sarıkaya M, Ertan K, Uğraş NS, Çiftçi İ, Yavaş G, et al. Çocuklarda primer böbrek tümörlerinin klinik özellikleri, tedavi yaklaşımları ve tedavi sonuçları. Genel Tıp Dergisi. 2021; 31(4): 375-379. google scholar
• Libes J, Hol J, Neto JCA, et al. Pediatric renal tumor epidemiology: Global perspectives, progress, and challenges. Pediatr Blood Cancer. 2023;70(1):e30006. google scholar
• Ünal E, Yilmaz E, Özcan A, Işik B, Karakükcü M, Turan C, et al. Twenty children with non-Wilms renal tumors from a reference center in Central Anatolia, Turkey. Turk J Med Sci. 2020 Feb 13;50(1):18-24. google scholar
• Brok J, Treger TD, Gooskens SL, et al. Biology and treatment of renal tumours in childhood. Eur J Cancer 2016;68:179-195. google scholar
• Jeffrey S. Dome EAM, Pedram Argani, Pediatric Renal Tumors, in Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. 2015, Saunders: Philadelphia. p. 1714-1746. google scholar
• Vujanic GM, Gessler M, Ooms AHAG, et al; International Society of Paediatric Oncology-Renal Tumour Study Group (SIOP-RTSG). The UMBRELLA SIOP-RTSG 2016 Wilms tumour pathology and molecular biology protocol. Nat Rev Urol. 2018 Nov;15(11):693-701. google scholar
• Turner JT, Brzezinski J, Dome JS. Wilms Tumor Predisposition. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; December 19, 2003. google scholar
• Richard H. Scott NR, Genetic Predisposition to Wilms Tumor, in Renal Tumors of Childhood, J.S.D. Kathy Pritchard-Jones, Editor. 2014, Springer: Berlin. p. 19-38. google scholar
• Pater L, Melchior P, Rübe C, et al. Wilms tumor. Pediatr Blood Cancer. 2021;68 Suppl 2:e28257. google scholar
• Perlman EJ, Grundy PE, Anderson JR, et al.WT1 mutation and 11p15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone: a Children’s Oncology Group study. J Clin Oncol. 2011;29:698-703. google scholar
• Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23:7312-7321. google scholar
• Vujanic GM, Sandstedt B, Harms D, et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol. 2002; 38(2):79-82. google scholar
• D’Angio GJ. The National Wilms Tumor Study: a 40 year perspective. Lifetime Data Anal. 2007;13(4):463-470. google scholar
• Kieran K, Anderson JR, DomeJS, et al. Is adrenalectomy necessary during unilateral nephrectomy for Wilms tumor? A report from the Children’s Oncology Group. J Pediatr Surg. 2013;48:1598-1603. google scholar
• Fernandez CV, Perlman EJ, Mullen EA, et al. Clinical outcome and biologic predictors of relapse after nephrectomy only for very low risk Wilms tumor: a report from the Children’s Oncology Group AREN0532. Ann Surg. 2017;265:835-840. google scholar
• Kalapurakal JA, Li SM, Breslow NE, et al. Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms’ tumor treated on NWTS-3 and NWTS-4: a report from the National Wilms Tumor Study group. Int J Radiat Oncol Biol Phys. 2003;57:495-499. google scholar
• Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms’ tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015;386:1156-1164. google scholar
• SIOP Renal Tumour Study Group. Paediatric renal tumours: perspectives from the SIOP-RTSG. Nat Rev Urol. 2017;14:3-4. google scholar
• Elmalı A, Sarı SY, Akyüz C, Gültekin M, Yalçın B, Ayrın B, et al. De-escalated Radiotherapy for Advanced Stage Wilms’ Tumor. Turk J Oncol 2023;38(1):66—74 google scholar
• Stokes CL, StokesWA, Kalapurakal JA, et al. Timing of radiation therapy in pediatric Wilms tumor: a report from the National Cancer Database. Int J Radiat Oncol Biol Phys. 2018;101:453-461. google scholar